评估转移性割抵抗性前列腺癌的第一线治疗策略:一个全面的网络元分析和系统审查
Duojie Zhang1, Haimin Weng1, Zhangji Zhu1
1The Second Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Frontiers in oncology
|April 30, 2024
概括
卡巴西塔塞尔20 mg/m2 + 普雷迪松 (C20P) 推用于转移性割抵抗性前列腺癌 (mCRPC) 的一线治疗,显示出改善的整体存活率 (OS) 和较少的严重不良事件 (SAE). 多西他塞尔 + 普得尼松 (DP) 是一个可行的替代品,特别是用于管理SAE.
科学领域:
- 在瘤学瘤学.
- 临床药理学 临床药理学
背景情况:
- 转移性割抵抗性前列腺癌 (mCRPC) 需要有效的第一线治疗来改善患者的治疗结果.
- 评估新疗法的比较疗效和安全性对于优化mCRPC管理至关重要.
结论:
- 建议使用卡巴西塔塞尔20 mg/m2 + 普雷迪尼松 (C20P) 作为mCRPC首选的第一线治疗方法.
- 多西他塞尔 + 普雷尼松 (DP) 是一个合适的替代品,特别是考虑到其安全性.
- 对于随后的治疗线,可以考虑使用恩扎胺和阿比拉,而-223是骨转移的选择.
更多相关视频
12:13Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
Published on: November 19, 2019
6.8K
06:44Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
Published on: September 8, 2017
13.3K
相关概念视频
Cancer Survival Analysis
345
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
345
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
